Figure 1.

RR estimates and 95% CIs for all-cause mortality (A), CVD mortality (B), and composite end point of CVD hospitalizations or CVD mortality (C) associated with combination therapy of metformin and sulfonylurea by study and pooled along with proportion of events for each outcome.